GrayBug Secures Worldwide Rights to Develop Proprietary Ophthalmic Drug Delivery Platforms


GrayBug raises $1mm from investors and is awarded a $200k grant to support research

Baltimore, MD – April 11, 2012 – GrayBug LLC announced today they have raised over $1 million in equity from investors and have successfully obtained the worldwide right to new technologies invented by GrayBug LLC co-founders Justin Hanes, Peter Campochiaro, and Peter McDonnell through a licensing deal with the John Hopkins University.

GrayBug was also awarded a $200k grant from The Maryland Biotechnology Center through their Biotech Development Program to support development of the company’s lead product targeting Age Related Macular Degeneration (AMD).

GrayBug is a biotechnology company that is developing proprietary controlled release technologies for pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases of the eye. GrayBug’s proprietary platform technology allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.

Related News

Press release

Graybug Vision Expands Executive Leadership Team with Key Hires

Redwood City, CA – December 11, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced Read more…

Press release

Graybug Vision to Participate in Upcoming Industry Conferences

Redwood City, CA – November 6, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced Read more…

Press release

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

– Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening Read more…